Stock Movement | Zhonghui Bio-B (02627) Surged Over 15% Intraday After Being Included in the Hang Seng Composite Index; Company Expected to Enter Through-Trading in March

Zhonghui Bio-B (02627) surged over 15% intraday and was up 8.93% at the time of writing, trading at HKD 56.1 with a turnover of HKD 19.373 million.

Zhitong FinanceFeb 16 10:03

ZH Bio-B has been included as a constituent stock of the Hang Seng Composite Index.

Zhonghui Bio-B (02627) announced that its H shares have been selected and will be included as a constituent stock of the Hang Seng Composite Index, effective from March 9, 2026. The Hang Seng Composite Index serves as a comprehensive indicator for H shares, covering companies listed on the main board of the Hong Kong Exchange with the highest accumulated market capitalization representing up to 95% of the total. It is widely adopted by index funds, mutual funds, and performance evaluation systems.

Zhitong FinanceFeb 16 08:26

HKEX Announcements Digest | CICC Projects Net Profit to Exceed 8.5 Billion Yuan in 2025; Great Wall Motor’s Annual Net Profit Declines by Approximately 20% Year-on-Year

①CICC is expected to generate a net profit of over 8.5 billion yuan in 2025. What is the year-on-year growth rate? ②Great Wall Motor's annual net profit declined by approximately 20% year-on-year. Which businesses were affected?

cls.cnJan 30 20:44

The trivalent subunit vaccine has been successfully approved, showcasing Zhonghui Bio-B's (02627) significant competitive advantage through differentiation.

Recently, Zhonghui Bio-B (02627) achieved another milestone — the successful approval and market launch of the first and only trivalent influenza virus subunit vaccine for the entire population nationwide.

Zhitong FinanceJan 30 17:47

Hong Kong Stock Ratings Summary: CICC Maintains Outperform Industry Rating for Alibaba

Cailian Press will regularly compile ratings and target prices from various institutions for Hong Kong stocks.

cls.cnJan 16 15:04

Zhonghui Biotech's gains expanded, with institutions noting the broad potential growth space for domestic flu vaccines.

ZH Bio-B rose nearly 8%, trading at HKD 46.6, with a turnover of HKD 19.2148 million.

Zhitong FinanceJan 15 14:23